Tempus Releases New Data at AACR Showcasing Ways to Analyze Multimodal Data to Highlight Potential Therapeutic Routes for HER2-Directed Antibody-Drug Conjugates in Several Tumor Types

April 08, 2024 at 09:30 AM EDT

Tempus, a leader in artificial intelligence and precision medicine, will present new data along with Pfizer at the AACR 2024 Annual Meeting. The abstract, titled “Analysis of HER2 prevalence by RNA expression across solid tumors,” found that by correlating HER2 protein levels by IHC/ISH and ERBB2 mRNA levels by NGS in tumors of patients with locally advanced/metastatic (LA/m) breast and gastric cancer, RNA expression in several solid tumors apart from breast or gastric cancer may correspond to HER2 IHC≥1+. These findings may open up potential therapeutic routes for HER2-directed antibody-drug conjugates in several tumor types.

In 2022, Seagen (acquired by Pfizer in December 2023) engaged Tempus to investigate cohorts of patients with HER2 RNA expression. As part of the collaboration, Tempus’ computational and real-world evidence teams helped provide insights on the prevalence of HER2 expression in select solid tumors. Pfizer is leveraging Tempus’ multimodal database to further its HEOR and Translational Science team’s research efforts.

“We’ve been fortunate enough to work alongside the Pfizer team as they expand their understanding of HER2 expression in solid tumors, which outside of breast and gastric cancers, has not been previously well described,” said Ryan Fukushima, Chief Operating Officer of Tempus. “For this specific study, we were able to tap into our existing database and analyze 4,500 de-identified records to support their research.”

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.